Scholarlink

<p>Ovarian neuroendocrine neoplasms (O-NENs) account for approximately 1–2% of all ovarian tumours. Two main histological subtypes of O-NENs can be distinguished: carcinoid tumours and neuroendocrine carcinomas, which differ significantly in their biological behaviour and, consequently, in their prognosis. What these neoplasms share, however, is the lack of clearly-defined clinical management, owing primarily to their rarity. In most cases, the neuroendocrine nature of these tumours is only identified upon histological examination, while the preoperative diagnostic pathway largely mirrors that used for epithelial ovarian tumours. Although interest in this neoplasm has grown in recent years, the literature mainly consists of case reports or small case series. Due to the lack of data from large patient populations, a shared and standardised management strategy has yet to be defined.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tumori neuroendocrini dell’ovaio: un nuovo scenario che avanza

  • 期刊论文

  • 发表日期：

    2025年11月11日

查看全文
  • Valentina Di Vito,
  • Gabriele Veroi,
  • Fiammetta Cipriani,
  • Norman Veccia,
  • Andrea Baiocchini,
  • Maria Cristina Macciomei,
  • Andrea Lania,
  • Lucia Rosalba Grillo,
  • Guido Rindi,
  • Roberto Baldelli

摘要

Ovarian neuroendocrine neoplasms (O-NENs) account for approximately 1–2% of all ovarian tumours. Two main histological subtypes of O-NENs can be distinguished: carcinoid tumours and neuroendocrine carcinomas, which differ significantly in their biological behaviour and, consequently, in their prognosis. What these neoplasms share, however, is the lack of clearly-defined clinical management, owing primarily to their rarity. In most cases, the neuroendocrine nature of these tumours is only identified upon histological examination, while the preoperative diagnostic pathway largely mirrors that used for epithelial ovarian tumours. Although interest in this neoplasm has grown in recent years, the literature mainly consists of case reports or small case series. Due to the lack of data from large patient populations, a shared and standardised management strategy has yet to be defined.